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Summary Ixabepilone (BMS-247550) is a semi-synthetic,
microtubule stabilizing epothilone B analogue which is
more potent than taxanes and has displayed activity in
taxane-resistant patients. The human plasma pharmacoki-
netics of ixabepilone have been described. However, the
excretory pathways and contribution of metabolism to
ixabepilone elimination have not been determined. To
investigate the elimination pathways of ixabepilone we
initiated a mass balance study in cancer patients. Due to
autoradiolysis, ixabepilone proved to be very unstable
when labeled with conventional [
14C]-levels (100 μCi in a
typical human radio-tracer study). This necessitated the use
of much lower levels of [
14C]-labeling and an ultra-
sensitive detection method, Accelerator Mass Spectrometry
(AMS). Eight patients with advanced cancer (3 males, 5
females; median age 54.5 y; performance status 0–2)
received an intravenous dose of 70 mg, 80 nCi of [
14C]
ixabepilone over 3 h. Plasma, urine and faeces were
c o l l e c t e du pt o7d a y sa f t e ra d m i n i s t r a t i o na n dt o t a l
radioactivity (TRA) was determined using AMS. Ixabepi-
lone in plasma and urine was quantitated using a validated
LC-MS/MS method. Mean recovery of ixabepilone-derived
radioactivity was 77.3% of dose. Fecal excretion was
52.2% and urinary excretion was 25.1%. Only a minor
part of TRA is accounted for by unchanged ixabepilone in
both plasma and urine, which indicates that metabolism is a
major elimination mechanism for this drug. Future studies
should focus on structural elucidation of ixabepilone
metabolites and characterization of their activities.
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Abbreviations
AMS Accelerator mass spectrometry
AUC Area under the plasma concentration versus
time curve
AUCinf AUC extrapolated to infinity
AUClast AUC until the time of the last quantifiable
measurement
AUMCinf Area under the first moment versus time
curve extrapolated to infinity
Cl Plasma clearance
Clrenal Renal clearance
Cmax Peak plasma concentration
DPM Disintegrations per minute
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Introduction
The taxanes paclitaxel and docetaxel are important anti-
cancer drugs [1]. However, their use is complicated by low
oral bioavailability and the development of resistance due
to MDR1 over-expression or β-tubulin mutation [2, 3]. A
search for microtubule stabilizing agents with improved
characteristics compared to taxanes led to the discovery of
epothilone A and B in extracts of the myxobacterium
Sorangium cellulosum [3], which were subsequently shown
to bind to tubulin at the same binding site as paclitaxel [4].
In vitro, epothilone B was more active than in vivo (mouse
models) [5], and in vivo hydrolysis of the lactone ring was
suspected of producing inactive metabolites. To improve
the metabolic stability of the naturally occurring epothi-
lones, these were modified by replacing the ester bond with
an amide bond [6, 7]. In general, lactam analogues
displayed tubulin-polymerizing and cytotoxic potencies
inferior to their naturally occurring counterparts. The
exception to this rule was the lactam analogue of epothilone
B, ixabepilone (BMS-247550, NSC 71028, EpoB-lactam,
aza-EpoB, 15-desoxy-15-aza-epothilone B), see Fig. 1 for
structure [6]. Ixabepilone has undergone a number of phase
II clinical trials with varying schedules at doses from 6 to
40 mg/m
2 administered as an intravenous infusion over 1 to
3h[ 8–11]. Response rates in metastatic breast (12–44%),
non-small cell lung (14%), hormone-refractory metastatic
prostate cancer (33%), and metastatic renal cell carcinoma
(14%) were modest to promising and warrant further
investigation [8]. The pharmacokinetics of ixabepilone
have been described [9,12, 13] and the contribution of
two known chemical degradation products was shown to be
negligible [14], however, other than that it is a CYP3A4/5
substrate [15], little is known about the excretion and
metabolic fate of ixabepilone.
The present investigation was aimed at determining the
pharmacokinetics and excretory pathways of [
14C]ixabepi-
lone. To this end, we initiated a mass balance study of
ixabepilone in humans. A mass balance is an elaborate
pharmacokinetic investigation employing a radioactive
tracer. It investigates the plasma pharmacokinetics and
excretion of both the unchanged drug and the total
radioactivity (drug and metabolites), and allows elucidation
of the metabolic fate of a drug. The main objective is the
maximum recovery of the radioactive dose in urine and
faeces [16]. Due to autoradiolysis, [
14C]ixabepilone at a
typical specific activity of 1.5 μCi/mg was unstable.
However, [
14C]ixabepilone at a specific activity of less
than 10 nCi/mg was found to be stable. Therefore a study
was conducted with a low radioactive dose of 80 nCi of
14C-ixabepilone, as opposed to a more typical human radio-
tracer dose of circa 100 μCi dosed in study. For detection of
these very low levels of radioactivity we used an ultra-
sensitive detection method, Accelerator Mass Spectrometry
(AMS) [17–19], which measures the amount of
14Ca si fi t
were a stable isotope label instead of measuring its decay.
AMS separates elemental isotopes through differences in
mass, charge, and energy, resulting in a [
14C]/[
12C] isotope
ratio. Subtracting the natural [
14C] background level and
taking into account the total carbon content of the sample
results in a total [
14C] amount that is converted to a
conventional unit for radioactivity (DPM, Bq, or Ci). Given
the very low dose of radioactivity administered (80 nCi
compared to 100 μCi in a typical radio-tracer study), ad-
ministration would result in negligible radiation exposure.
Materials and methods
Study design
This was an open-label, single-dose study in which eight
patients with histologically confirmed solid tumours re-
ceived an intravenous fixed dose of 70 mg, 80 nCi [
14C]
ixabepilone over 3 h. The protocol and informed consent
form were reviewed and approved by the Institutional
Review Board of the Antoni van Leeuwenhoek Hospital/
The Netherlands Cancer Institute, and each patient gave
written informed consent before receiving the study
medication. Eligibility criteria most relevant to the mass
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Fig. 1 Chemical structures of epothilone B and its lactam analogue
ixabepilone
328 Invest New Drugs (2007) 25:327–334balance study were: availability for in-house admittance
during the first 8 days, adequate hepatic and renal function,
a performance status (PS) of 0–2, and a life expectancy of
at least 12 weeks.
Patients
Eight patients (three male and five female) with a median
age of 54.5 years and a WHO performance status of 0–2
were enrolled in the study. All patients had advanced cancer
for which no standard anti-cancer therapy was available.
The primary tumours were: squamous cell carcinoma, colon
cancer (n=2), gastric carcinoma, ovarian cancer, non-small
cell lung cancer, sigmoid adenocarcinoma, and pancreas
carcinoma.
Study medication
Individual vials of radiolabeled ixabepilone contained
20 mg, 22.8 nCi [
14C]ixabepilone (specific activity
1.14 nCi/mg). The [
14C]ixabepilone was synthesized by
Bristol-Myers Squibb by growing the myxobacterium
Sorangium cellulosum in
14C containing medium. This
resulted in labeling throughout the ixabepilone molecule.
Radiochemical and chemical purity was confirmed at
>99%. Vials were reconstituted using 10 ml Cremo-
phor®EL:ethanol (1:1, v/v) each. A 35 ml volume of the
reconstituted [
14C]ixabepilone was added to 140 ml Lac-
tated Ringer’s Infusion (LRI). After mixing, a 2 ml sample
was taken for quantitation of radioactivity by liquid
scintillation counting (LSC). LSC radioactivity values were
recalculated to amounts of [
14C]ixabepilone for use in
calculating recovery from feces and urine. After the 3-
h intravenous administration, infusion lines were flushed
with 500 ml LRI. Gravimetric measurements of the infusion
flask prior to, and after administration enabled calculation
of the amount of radioactivity actually administered. To
prevent Cremophor®EL-related hypersensitivity reactions,
patients were pre-medicated with oral H1 and H2 blockers.
Sample collection
Blood was collected at 0 (pre-dose), 1.5, 3 (prior to end of
infusion), 3.25, 3.5, 3.75, 4, 5, 6, 8, 12, 24, 48, 72, 120, and
168 h after start of infusion. An indwelling catheter contra-
lateral to the administration site was used for serial blood
sampling. Separate, but simultaneous, blood samples were
taken for the quantitation of total radioactivity and
unchanged ixabepilone, respectively. Plasma was obtained
by immediate centrifugation of the blood (10 min, 1000×g,
4°C). The plasma layer was aspirated and stored below
−20°C until analysis. We collected complete urinary and
faecal output up to 7 days after administration. Urine was
collected over 24-h intervals in refrigerated collection jugs.
At the end of each collection interval, the respective urine
samples were mixed and total volume was recorded.
Aliquots were stored below −20°C until analysis. Faecal
samples were collected and stored at −20°C per portion and
combined per 24-h interval. Faeces were homogenized after
addition of water (2:1, w/w). Aliquots were stored below
−20°C until analysis.
AMS analysis of total radioactivity (TRA) in plasma, urine
and faeces
TRA in plasma, urine and faeces was determined using
AMS (Exceleron, York, UK) [20, 21]. Briefly, sample pre-
treatment consisted of the conversion of the carbon within
the samples to graphite via a two-step process of oxidation
and reduction [22]. Oxidation (combustion) was performed
by heating the dried sample with copper oxide under
vacuum at 900°C for 2 h in a heat-sealed tube. Reduction
(graphitisation) was performed by heating the carbon
dioxide formed from the oxidised sample with zinc,
titanium hydride and cobalt at 500°C for 4 h, followed by
a further 6 h at 550°C. After the graphitisation process, the
graphite was pressed into a cathode. In the AMS-procedure,
this cathode was bombarded with high-energy caesium
(Cs
+) ions. The resulting negative carbon ion beam was
introduced into the AMS instrument, accelerated by an
electric field of 4.5 MV, and the carbon atoms were stripped
of their valency electrons. This resulted in separation of the
carbon isotopical elements as C
4+ ions. The carbon isotopes
12C and
13C were quantitated using Faraday cups, while
14C was quantitated by a gas ionization detector. Because
AMS provides an isotope ratio that is [
14C]/[
12C] and not an
absolute value, it is necessary to know the carbon content
of the sample plus any added carrier. This was determined
using a carbon, hydrogen, nitrogen analyser (Elemental
Microanalysis Ltd., Okehampton, UK). The natural back-
ground [
14C]/[
12C] level per matrix was subtracted to obtain
the amount of ixabepilone-related
14C. The total carbon
content and the specific activity of [
14C]ixabepilone was
used to convert the [
14C]/[
12C] ratio to ixabepilone
equivalents (ng/ml sample or % of dose). Using this
sophisticated technique, it was possible to quantitate <4
DPM/ml plasma, 0.01 DPM/ml urine and 0.1 DPM/g faeces
(1 DPM corresponds to 395 ng [
14C]ixabepilone).
Analysis of ixabepilone in plasma and urine
Concentrations of ixabepilone parent drug in plasma and
urine were determined with a validated liquid chromatog-
raphy assay equipped with tandem mass spectrometric
detection (Bristol-Myers Squibb, Princeton, NJ). Briefly,
Invest New Drugs (2007) 25:327–334 329after addition of internal standard (BMS-212188) to 0.2 ml
of each sample, calibration standard and quality control
sample, the samples were precipitated with acetone. The
supernatant was further extracted with 1-chlorobutane. The
organic layer was removed and evaporated to dryness.
The residue was reconstituted and injected into the LC-MS/
MS system. Chromatographic separation was achieved,
isocratically, on a YMC ODS-AQ column (4.6×50 mm
internal diameter) at a flow rate of 0.3 ml/min with
detection by electrospray tandem mass spectrometry. The
mobile phase contained acetonitrile—0.01 M ammonium
acetate (pH 5.0) (65:35, v/v). The standard curve, which
ranged from 2 to 500 ng/ml, was constructed with a 1/x
weighted quadratic regression model. The within-run
precision for ixabepilone in plasma and urine was within
15 and 9%, respectively. The between-run precision for
ixabepilone in plasma and urine was within 13 and 9%,
respectively. The accuracy was within 11 and 6% of the
nominal values in plasma and urine, respectively.
Pharmacokinetic analyses
The pharmacokinetic analyses of the ixabepilone plasma
concentration versus time data were performed by non-
compartmental methods using Kinetica Version 4.2 (Inna-
Phase Corporation, Philadelphia, PA). The peak plasma
concentration (Cmax) and the time to reach maximal
concentration (Tmax) represent observed values. The area
under the plasma concentration versus time curve (AUC)
was calculated using a combination of linear and log trape-
zoidal summations. The AUC was extrapolated to infinity
(AUCinf) by dividing the last measurable concentration by
the terminal rate constant, k. The absolute value of k was
used to estimate the apparent terminal half-life, t1/2=ln2/k.
The total body clearance (Cl) was determined by dividing
dose by AUCinf and the volume of distribution at steady-
state (Vss) was calculated as dose × area under the moment
curve (AUMCinf)/(AUCinf)
2 with appropriate corrections
for infusion duration. Renal clearance was calculated by
dividing amount excreted by the AUC. Similarly, pseudo-
pharmacokinetic parameters were calculated for TRA.
Outliers were statistically assessed using Dixon’s Q test.
Results
To evaluate the pharmacokinetics and excretory pathways
of [
14C]ixabepilone, we performed a mass balance study in
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Fig. 2 Mean (±SD) plasma concentration-time curves of [
14C]
ixabepilone derived radioactivity ( filled square) and unchanged
[
14C]ixabepilone (open square) for eight patients
Table 1 Plasma pharmacokinetic parameters of ixabepilone and total radioactivity in cancer patients after a 3 h intravenous infusion of 70 mg,
80 nCi [
14C]ixabepilone
Nr Ixabepilone Radioactivity (ixabepilone equiv.) AUClast ratio
a
Cmax
(ng/ml)
AUClast
(μg*h/ml)
AUCinf
(μg*h/ml)
t1/2(h) Cl (l/h) Vss (l) Cmax
(ng/ml)
AUClast
(μg*h/ml)
AUCinf
(μg*h/ml)
t1/2 (h)
1 277 3.06 3.35 51.7 20.9 1275 322 1.89 1.96 8.3 1.62
b
2 287 2.75 2.97 53.0 23.6 1174 497 11.0 11.8 48.7 0.25
3 433 2.83 2.99 51.7 23.4 929 681 10.9 11.3 36.5 0.26
4 486 3.82 4.32 67.4 16.2 1027 940 20.1 21.6 46.9 0.19
5 266 2.42 2.52 23.5 27.8 756 503 20.0 44.3 185.2 0.12
6 273 2.17 2.29 36.7 30.5 912 573 11.9 16.3 99.8 0.18
7 201 2.25 2.49 71.5 28.1 1520 449 8.53 9.59 61.2 0.26
8 187 1.93 2.22 47.2 31.6 1635 1502 32.5 34.4 34.4 0.06
Mean 301 2.65 2.89 50.3 25.3 1154 683 16.4
b 21.3
b 73.1
b 0.19
b
SD 105 0.60 0.69 15.4 5.2 308 378 8.44
b 13.2
b 54.0
b 0.08
b
aAUClast ratio is calculated by dividing AUClast ixabepilone by AUClast TRA and expresses the relative contribution of ixabepilone to TRA
exposure in plasma.
bPatient 1 was not included in the calculation because the radioactivity AUC and t1/2 could not be determined accurately (see text). This also
resulted in the deviating AUClast ratio (outlier).
330 Invest New Drugs (2007) 25:327–334eight patients. Figure 2 shows the mean plasma concen-
trations over time of both TRA and ixabepilone as
determined by AMS and LC-MS/MS, respectively.
Both TRA and ixabepilone in plasma exhibited an initial
distribution phase of approximately 10 h followed by a
much slower terminal elimination phase with half-lives of
73.1 and 50.3 h, respectively. The time to maximum plasma
concentration was typically around the end of infusion.
Plasma ixabepilone concentrations were quantifiable
through 168 h in all patients and plasma TRA concen-
trations were quantifiable through 168 h in all patients
except in patient 1 in whom plasma TRA concentrations
were only quantifiable for 48 h. Pharmacokinetic parame-
ters are summarized in Table 1. The ratio of the ixabepilone
AUC to the total radioactivity AUC, or AUC-ratio, is a
measure of exposure to [
14C]ixabepilone relative to total
[
14C]ixabepilone related compounds. The AUC ratio of
patient 1 was larger than unity. This was caused by the
underestimated TRA AUC, which was based on measure-
ments until only 48 h, after which plasma concentrations
fell below the lower limit of quantitation. Besides the TRA
AUC, the t1/2 of patient 1 was also inaccurately estimated at
8.3 h. Therefore, patient 1 was omitted from calculation of
mean plasma TRA parameters. Figure 3 shows the plasma
concentrations of ixabepilone relative to TRA for patients
1–7 and patient 8. Patient 8 experienced a blocked bile duct
(reflected by a maximum plasma bilirubin concentration of
47 μmol/l (3 × upper limit of normal) and alkaline phos-
phatase of 500 U/l (4 × upper limit of normal) at day 7)
resulting in a higher plasma TRA, Cmax and AUC. The
higher TRA plasma concentrations in patient 8 resulted in
an AUC ratio of plasma ixabepilone to TRA that was lower
than that of the other patients. In contrast, unchanged
ixabepilone plasma pharmacokinetics were not affected in
this patient.
Figure 4 displays the mean excretion of TRA in urine
and faeces and the total, in time, and Fig. 5 displays the
mean cumulative urinary excretion of [
14C]ixabepilone
derived radioactivity and unchanged [
14C]ixabepilone.
Table 2 shows individual 168 h excretions of [
14C]
ixabepilone and TRA in urine and faeces. The U/F ratio is
the ratio of urinary recovery relative to faecal recovery.
Patient 3 displayed a rather low recovery of radioactivity
from both urine (14.8%) and faeces (38.3%). Plasma
pharmacokinetics were not different compared to the other
patients. A low total recovery of 37.8% was also obtained
for patient 4, attributable to a very low faecal recovery
(12.7%), while urinary recovery was normal (25.1%). This
patient only defecated at 24 h and at 168 h (a few grams),
which almost certainly explains the observed low recovery.
Although the plasma pharmacokinetics and urinary excre-
tion did not deviate extremely from the other patients,
patient 4 displayed a somewhat elevated plasma exposure
to both radioactivity and ixabepilone, and the lowest
clearance for unchanged ixabepilone. If we now look at
the U/F ratios (a measure of urinary versus faecal
elimination), patient 4, who had the low fecal output, is
an outlier (Q=0.86, critical value p=0.05: 0.57) compared
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14C]ixabepilone to total radioactivity ratio in
plasma over time for patients 1–7(filled square) and patient 8 (open
square)
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and total ( filled square, +SD) cumulative excretion (168 h) of [
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ixabepilone derived radioactivity for eight patients
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Fig. 5 Mean (±SD) cumulative urinary excretion of [
14C]ixabepilone
derived radioactivity ( filled square) and unchanged [
14C]ixabepilone
(open square) for eight patients
Invest New Drugs (2007) 25:327–334 331to patients 1, 2, 3, 5, 6 and 7. Patient 8, who experienced
the blocked bile duct stent, is also an outlier (Q=0.91,
critical value p=0.05: 0.52) compared to the same patients.
The urinary recovery of patient 8 was highest at 47.7%
causing the large standard deviation of urinary recovery.
However, the urinary recovery of unchanged ixabepilone of
4.0% was within the normal range. The faecal recovery of
this patient was the lowest (excluding patient 4) at 15.6%.
Apparently, there was no accumulation of the active drug
despite a decreased biliary excretion.
On average, more than 77% of the drug was excreted
over the 7-day period with the majority of 52% being
excreted in faeces and 25% in urine. Excretion in faeces
occurredatarelativelyconstantrateovertheentirecollection
period, with only 10 and 12% of dose recovered in the 0–24
and 24–48 h collection intervals, respectively. In contrast,
urinary excretion displayed two distinct phases with 65% of
totalurinaryradioactivity(correspondingto17%ofdose)and
76% of total urinary ixabepilone being excreted in the first
24 h. From 24 to 168 h, urinary excretion occurred at a
relatively slow constant rate. This may reflect the biphasic
plasma curve, with high concentrations in the distribution
phase and lower concentrations in the terminal elimination
phase. At first urinary excretion predominates and after 24 h,
faecal excretion becomes the dominant route of excretion.
Discussion
The present investigation was aimed at determining the
pharmacokinetics and excretory pathways of [
14C]ixabepi-
lone by performing a mass balance study.
In conventional human mass balance studies, approxi-
mately 100 μCi of [
14C] is typically used to trace the fate of
a drug [16]. Due to autoradiolysis of ixabepilone, this level
of labeling was not possible. The level of radioactive
labeling we used was more than 1,000-fold lower at 80 nCi.
The most commonly used method for detection of radio-
tracers in mass balance studies is liquid scintillation
counting (LSC). This method however, relies on the
detection of β-emissions and therefore can only exploit a
very small proportion of the isotope.
14C has a half-life of
5740 years and therefore only about 0.012% of the
14C
atoms in a sample decay over the course of a year. AMS
however, is a nuclear physics technique that detects the
individual
14C atoms, as if they were stable isotopes, and is
therefore much more sensitive than LSC [19]. Originally,
AMS technology was developed in the 1970s for radiocar-
bon dating, but has recently found novel uses in biomedical
research. It has been used to study DNA adducts of
carcinogens, and it can replace decay counting as a method
of analysis in biological samples [17, 23–25]. A first human
mass balance using this ultra-sensitive technique has
already been reported and is expected to be followed by
many others [26].
The ixabepilone plasma pharmacokinetic parameters
observed in the present investigation are similar to the
values previously reported for a standard phase I dose
escalation study in which 11 patients were administered
40 mg/m
2 of ixabepilone in an expansion of the recom-
mended phase II dose [9]. However, in our study, the
coefficient of variation for AUCinf and Cl of ixabepilone
was 24 and 21% as compared to 46 and 38% in the phase I
dose escalationstudy.The lower inter-patient variability may
Table 2 Urinary and faecal recovery (0–168 h) of ixabepilone and total radioactivity in cancer patients after a 3 h intravenous infusion of 70 mg,
80 nCi [
14C]ixabepilone
Nr
a Recovery (% of dose) Radioactivity (U/F ratio
c) Ixabepilone (Clrenal (l/h))
Ixabepilone Total radioactivity
Urine Urine Faeces Total
1 5.07 14.56 59.69 74.25 0.24 1.16
2 4.66 23.28 74.78 98.06 0.31 1.19
3 7.76 14.77 38.29 53.06 0.39 1.92
4 3.32 25.08 12.71 37.79 1.97 0.61
5 5.46 19.66 65.02 84.68 0.30 1.58
6 6.12 30.78 64.59 95.37 0.48 1.98
7 6.03 25.05 86.72 111.77 0.29 1.87
8 4.02 47.65 15.62 63.27 3.05 1.46
Mean 5.30 25.10 52.18 77.28 0.33
b 1.47
SD 1.38 10.63 27.17 24.94 0.08
b 0.47
aPatients 1, 2, and 8 were male.
bPatient 4 was not included because of the extremely low production of faeces and patient 8 was not included in the calculation because his bile
duct obstruction (relevance illustrated by increasing plasma bilirubin concentrations) may have reduced faecal excretion.
cThe U/F ratio is the ratio of urinary recovery relative to faecal recovery.
332 Invest New Drugs (2007) 25:327–334result from the greater rigor toward sample collection and
processing that is possible in a mass balance study during
which the patient is hospitalized. It should also be noted that
the administration of ixabepilone as a flat 70 mg dose in the
present study did not result in any increase in inter-patient
variability compared with the dose, based on body surface
area, which was administered during the phase I study.
Our results show that ixabepilone is extensively metab-
olised. This is indicated by the plasma AUC ratio of 0.19
and confirmed by the recovery of ixabepilone relative to
TRA in urine of approximately 0.21. Patient 8 experienced
a blocked bile duct resulting in a higher plasma TRA, Cmax
and AUC, but interestingly, unchanged ixabepilone plasma
pharmacokinetics were not affected and excretion of
ixabepilone metabolites was re-routed to urine.
The calculated half-life of TRA was longer than that of
ixabepilone (t1/2 of 73.1 and 50.3 h respectively), however,
we do not conclude that TRA was eliminated more slowly
than ixabepilone. Comparison of ixabepilone and TRA
half-lives per patient revealed that in 5 cases (patient 2, 3, 4,
7, and 8) the TRA half-life was shorter than the ixabepilone
half-life. The mean TRA half-life was disproportionally
influenced by the long half-life observed in patient 5
(185 h). The very long half-life of TRA in this patient is not
likely to be clinically relevant because this patient excreted
85% of the dose within 7 days. Based on the half-lives for
plasma radioactivity observed in the other patients, in the
once every 3 weeks administration schedule, accumulation
of metabolites should not occur. The seemingly long
ixabepilone half-life of over 50 h is not unusual when
compared to other tubulin-interacting drugs. Half-lives of e.
g. vinca-alkaloids range from 12–42 h for vindesine and up
to a half-life of several days for vincristine.
With an average recovery of 77% of the drug excreted
over the 7-day period, the recovery of radioactivity of this
mass balance study is reasonably good [16]. The incom-
plete recovery is explained by the still ongoing excretion at
the end of the 7 day collection period, and the long plasma
half-life of TRA. Immediate assessment of the still appre-
ciable amounts of radioactivity excreted on day 7 to possi-
ble extend the period of collecting excreta, as suggested in
the literature [16], was not possible. The shipping and lag-
time in quantitating radioactivity by AMS precluded this.
Another contributing route of elimination not monitored in
the current study is loss of radioactivity through expiration
of
14CO 2 [16]. At 52% of the dose versus 25%, faecal
excretion is a quantitatively more important route of elimi-
nation than urinary excretion. Biliary excretion is governed
by a molecular weight limit. In humans, polar compounds
with a molecular weight above approximately 500 g/mol
are predominantly excreted via bile [27, 28]. Ixabepilone
metabolites will probably be more polar (phase I me-
tabolism, oxidation, hydrolysis etc.) and have higher
masses (conjugates or phase II metabolites) than ixabepi-
lone (Mwt 506.7 g/mol, and rather hydrophobic). Whether
this is the case for ixabepilone remains to be investigated
by metabolic profiling of the excreta.
Given the normal ixabepilone plasma concentrations of
patient 8 while experiencing a blocked bile duct, biliary
excretion of unchanged ixabepilone into faeces may not be
a very important elimination route, and the results suggest
that ixabepilone was equally well metabolised but that the
biliary excretion of these metabolites was hindered by the
blocked bile duct stent, resulting in a shift to urinary
excretion of total radioactivity.
The importance of metabolism in the elimination of
ixabepilone has been confirmed by this study as apparent
from the low contribution of unchanged ixabepilone to
TRA in plasma and urine. Ixabepilone related radioactivity
is predominantly excreted in the faeces. Future investiga-
tions must be aimed at elucidating the metabolic fate of
ixabepilone, and determining the activity of the metabolites.
Subsequent identification of drug metabolizing enzymes
involved in ixabepilone metabolism may result in explain-
ing pharmacokinetic variability of ixabepilone in individual
patients.
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